secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-151999
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim
--------------------------------------------------------------------------------

- 58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.
- No CRS, ICANS, or GvHD reported; 10 of 12 cema-cel patients managed fully outpatient.
- Plasma ctDNA decreased 97.7% median in cema-cel arm vs 26.6% increase in observation at Day 45.
- Cema-cel arm had more aggressive disease (100% stage III-IV, 41.7% IPI 4-5) than observation.
- ALPHA3 targets ~220 patients; enrollment complete by end 2027; interim EFS mid-2027, primary mid-2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526151999/0001193125-26-151999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526151999/d49895d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-151999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer